INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Company to Host Conference Call Today, November 1, at 4:30pm ETBOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update. Q3 2023 Corporate Highlights: DN-TNF Platform Highlights (XPro™): AD02 blinded randomized p

Related Keywords

Athens ,Attikír ,Greece ,Netherlands ,Canada ,United States ,Berlin ,Germany ,Australia ,Raton ,Perifereia Peloponnisou ,United Kingdom ,Amsterdam ,Noord Holland ,American ,Inmune Biocontact ,David Moss ,Jason Nelson ,Inmune Bio ,Financialresultsforthe Quarterended ,Inmune Bio Inc ,European Meeting On Glial Cells In Health ,Company To Host Conference Call ,Nasdaq ,Food Drug Administration ,World Intellectual Property Organization ,United States Patent Trademark Office ,Company Annual Report On Form ,Society Of Immunotherapy ,Company Current Reports On Form ,Alzheimer Association International Conference ,Company Quarterly Reports On Form ,Exchange Commission ,International Search Authority ,Regulatory Agency ,Drug Administration ,Host Conference Call Today ,Early Alzheimer ,Clinical Trial Application ,Association International Conference ,European Meeting ,Glial Cells ,Bayesian Phase ,United States Patent ,Trademark Office ,Patent Cooperation Treaty ,American Type Culture Collection ,Treatment Resistant Depression ,Resultsforthe Quarterended September ,Bio Third Quarter Conference Call ,Dominant Negative Tumor Necrosis Factor ,Mild Alzheimer ,Mild Cognitive Impairment ,Natural Killer Cell Priming Platform ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Nine Months Ended ,Nine Months ,The Company ,Alzheimers Disease ,Product Development ,Innate Immune System ,Pro ,Neurodegenerative Diseases ,Clinical Trials ,Clinical Trial ,Tumor Necrosis Factor ,Nasopharyngeal Cancer ,Phase Ii Trial ,Grey Matter ,Company ,Research And Development ,